Hyaluronic Acid Test

Your liver enzymes can look perfectly normal while scar tissue quietly builds inside your liver. Standard blood panels measure whether liver cells are being damaged right now, but they say nothing about whether that damage is leaving permanent scars behind. Serum hyaluronic acid (HA) fills that gap. It rises when your liver's cleanup system is overwhelmed, when your joints are wearing down faster than they should be, or when inflammation is tearing through your connective tissues.

HA is a large carbohydrate chain (a glycosaminoglycan, one of the sugar-based molecules that give your tissues their structure) that lives in the spaces between your cells. Your body produces it constantly, and your liver clears it from your blood with a half-life of just 2 to 5 minutes. When the liver's filtering cells are damaged by scarring, or when tissues are producing far more HA than normal, serum levels climb. That makes HA one of the most direct blood-based signals of how much structural damage is accumulating in your body.

Liver Fibrosis and Cirrhosis

Liver scarring (fibrosis) is the primary clinical use for serum HA testing. When the liver is injured repeatedly, whether by excess fat accumulation, alcohol, or viral infection, specialized repair cells called hepatic stellate cells activate and begin producing scar tissue along with large amounts of HA. At the same time, the liver's own HA-clearing cells become damaged by the scarring process. The result is a double hit: more HA is being made and less is being removed.

The numbers tell the story clearly. Healthy adults average about 23 micrograms per liter of serum HA. People with alcoholic cirrhosis average 1,225 micrograms per liter, more than 50 times higher. Primary biliary cirrhosis produces averages around 792 micrograms per liter, and viral hepatitis cirrhosis around 649 micrograms per liter. These are not subtle shifts.

HA is most commonly used as part of the Enhanced Liver Fibrosis (ELF) panel, which combines it with two other markers of scar tissue turnover: TIMP-1 (a protein that prevents scar breakdown) and PIIINP (a fragment released when new collagen is being laid down). The ELF panel is recommended by the AASLD as a second-line assessment for people whose initial screening score (FIB-4) comes back in the gray zone. An ELF score of 9.8 or above flags you as higher risk for progression to cirrhosis and liver-related complications.

Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD) now affects roughly one in four adults worldwide. Most people with fatty liver will never develop serious complications, but a subset progress to active liver inflammation (steatohepatitis) and fibrosis. Identifying who is progressing is the central challenge, and HA-containing panels are one of the best blood-based tools for doing so.

The American Diabetes Association's 2025 consensus report recommends fibrosis screening for all people with type 2 diabetes, using FIB-4 as a first step and the ELF test as an alternative second-tier tool when liver stiffness imaging is not available. For people with FIB-4 scores in the indeterminate range (1.3 to 2.67), an ELF score below 9.8 can provide reassurance, while a score at or above 9.8 warrants referral to a liver specialist.

Joint Disease

HA is a major component of the fluid that lubricates your joints and the cartilage that cushions them. When joints break down, HA turnover accelerates and serum levels rise. In a five-year prospective study of 444 individuals from the Iwaki cohort, higher baseline serum HA predicted faster narrowing of the knee joint space in both people with established osteoarthritis and those with normal-appearing knees at the start of the study.

A separate six-year follow-up from the same cohort found that serum HA levels were significantly higher in people who had hand osteoarthritis compared to those who did not, and that higher baseline levels predicted both the development of new hand osteoarthritis and the progression of existing disease. In a cross-sectional study of 616 volunteers, serum HA levels rose in step with osteoarthritis severity, with significantly higher values in moderate and severe disease compared to normal joints.

Inflammatory Conditions

Rheumatoid arthritis drives serum HA sharply upward. In one study, RA patients averaged 232 micrograms per liter compared to 42 micrograms per liter in healthy controls. Levels tracked with disease activity, correlating more tightly with swollen joint counts and physician-assessed severity than either ESR or CRP. Serum HA also rises in systemic vasculitis (inflammation of the blood vessels), where it follows disease activity and reflects the extent of tissue damage.

In critical illness, HA levels climb in proportion to organ dysfunction and disease severity. Sepsis produces particularly high levels, and elevated HA in the intensive care setting is associated with worse outcomes. This reflects both increased HA release from damaged blood vessel linings (a process called glycocalyx shedding, where the protective sugar coating on blood vessel walls breaks apart) and impaired liver clearance during systemic illness.

Kidney Disease

Kidney failure significantly elevates serum HA through altered connective tissue metabolism in the setting of chronic uremia (the buildup of waste products when kidneys fail). Hemodialysis patients show median levels of 167 micrograms per liter, roughly seven times the median in healthy controls. HA is not removed by hemodialysis, and levels correlate with the duration of dialysis treatment rather than the degree of kidney dysfunction itself. In one study, high serum HA independently predicted poor survival in people on kidney replacement therapy.

Reference Ranges

HA levels change substantially with age. Before interpreting your result, you need to know that people over 50 tend to have naturally higher levels than younger adults, even without disease. This age-related increase likely reflects a combination of slower liver clearance and increased tissue turnover.

These values are drawn from published research using hyaluronic acid binding protein (HABP) assays. Your lab may use different methods with slightly different cutpoints. The most meaningful comparison is always your own number tracked over time within the same lab.

For liver fibrosis specifically, standalone HA above roughly 100 micrograms per liter in a middle-aged adult begins to raise concern. But HA is most useful as part of the ELF panel, where a composite score of 9.8 or above indicates elevated risk for advanced fibrosis. The NICE guidelines in the UK use a higher ELF threshold of 10.51 for specialist referral, trading some sensitivity for higher specificity (correctly identifying 93 out of 100 people who do not have advanced fibrosis).

Why One Reading Is Not Enough

Serum HA has one of the highest within-person variability rates of any commonly measured biomarker. In healthy individuals, the week-to-week coefficient of variation is 34% to 62%. In people with chronic hepatitis C or fatty liver disease, it runs 34% to 45%. This means a single reading can bounce around considerably even when nothing has changed in your health.

That variability makes trending your results over time far more informative than reacting to any single number. Get a fasting baseline, then retest in 6 months if you are making lifestyle changes to address liver health or joint issues. After that, annual monitoring keeps you on track. If you are managing known fibrosis at stage F2 or higher, more frequent testing every 6 months helps you gauge whether your interventions are working. The key rule: a change only counts if it exceeds the reference change value for this test, which is roughly 50% to 80% depending on disease context. Smaller shifts are likely just noise.

When Results Can Be Misleading

Food intake is the single biggest confounder for serum HA. Eating a meal can spike your level 1.7 to 13 times above baseline within 45 to 90 minutes, pushing a healthy person into ranges that would suggest liver fibrosis. This happens because nutrients trigger increased blood flow to the gut, which flushes HA from intestinal tissues into the bloodstream. Always test fasting.

Physical activity causes a biphasic swing. During exercise, HA rises 27% to 76% above baseline depending on intensity. Then, 15 to 30 minutes after you stop, levels drop about 43% below baseline as the liver ramps up clearance. If you exercise the morning of your blood draw, your result could be falsely low. Test before any significant physical activity, and try to sample at a consistent time of day, since HA shows a morning spike in the first 0.5 to 2 hours after getting out of bed.

Several conditions outside the liver can elevate HA and produce misleading results. Kidney failure, rheumatoid arthritis, sepsis, systemic vasculitis, interstitial lung disease, prior gastrectomy, and certain cancers (particularly mesothelioma and Wilms' tumor) all push HA higher for reasons unrelated to liver fibrosis. If your HA is elevated and you have any of these conditions, the result cannot be interpreted as a liver fibrosis marker without additional context.

Corticosteroids reduce HA synthesis by roughly 40% to 60% in laboratory studies, and clinical data confirm that steroid treatment lowers serum HA in patients. If you are taking prednisone or a similar steroid for another condition, your HA result may be artificially low, potentially masking real fibrosis. Interferon-alpha for hepatitis B treatment can push HA upward independently of fibrosis changes. NSAIDs, by contrast, do not affect HA levels. Active alcohol consumption elevates HA in people with alcoholic liver disease beyond what their fibrosis stage alone would predict; levels can fall back to expected ranges after about four weeks of abstinence.